A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
Dear Colleagues, I am delighted you are able to join the roundtable discussion and working lunch with Bill Gates on Monday, December 2, from 12:15 AM-1:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with Bill and other staff from the Global Health Program at the BMGF. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than a series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to discuss the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD); Trevor Mundel, President of the Global Health Program at the BMGF; Boris Nikolic, Scientific Advisor; and Kathy Young, Senior Project Manager for Strategic Planning and Engagement. Their bios are attached. Please feel free to contact Rob Eiss at FIC with any questions you or your staff may have surrounding the visit. I'm delighted that Bill was able to reschedule so soon after the shutdown, and will remain on campus a good portion of the day to visit labs and hold discussions with senior leadership, in addition to the presenting the annual David Barmes Global Health lecture. Best regards, Francis or In that you comment 1) the state of ad discussion. 2eping flexible ' this format
-
Dear Colleagues, I am delighted you are able to join the roundtable discussion and working lunch with Bill Gates on Monday, December 2, from 12:15 AM-1:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with Bill and other staff from the Global Health Program at the BMGF. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than a series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to discuss the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD); Trevor Mundel, President of the Global Health Program at the BMGF; Boris Nikolic, Strategic Planning and Engagement. Their bios are Scientific Advisor; and Kathy Young, Senior Project Manager for Strategic Planning and Engagement. Their bios are attached. Please feel free to contact Rob Eiss at FIC with any questions you or your staff may have surrounding the visit. I'm delighted that Bill was able to reschedule so soon after the shutdown, and will remain on campus a good portion of the day to visit labs and hold discussions with senior leadership, in addition to the presenting the annual David Barmes Global Health lecture. Best regards, Francis
-
2013-11-24 12:38
Francis S. Collins
Dear Colleagues, I am delighted you are able to join the roundtable discussion and working lunch with Bill Gates on Monday, December 2, from 12:15 AM-1:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with Bill and other staff from the Global Health Program at the BMGF. In that you comment 1) the state of ad discussion. 2eping flexible ' this format strategic Planning and Engagement. Their bios are Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than a series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to discuss the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD); Trevor Mundel, President of the Global Health Program at the BMGF; Boris Nikolic, Scientific Advisor; and Kathy Young, Senior Project Manager for Strategic Planning and Engagement. Their bios are attached. Please feel free to contact Rob Eiss at FIC with any questions you or your staff may have surrounding the visit. I'm delighted that Bill was able to reschedule so soon after the shutdown, and will remain on campus a good portion of the day to visit labs and hold discussions with senior leadership, in addition to the presenting the annual David Barmes Global Health lecture. Best regards, Francis (ibility on Dr. Tabak's calendar for the visit, ies and I will provide nce team is here today for the ould From: "Jin, Daozhong (NIH/OD) [C]" </O=NIH/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=JINDAO> To: "Eiss, Robert (NIH/FIC) [E]" @mail.nih.gov> Subject: RE: Agenda for Bill Gates visit to NIH on December 2 Date: Mon, 25 Nov 2013 09:06:55 -0500 Importance: Normal Thanks again for the information, Robert! I'm making sure to keep plenty of flexibility on Dr. Tabak's calendar for the visit, so there's no hurry, I'll keep an eye out of the itinerary whenever it is ready.
-
Dear Colleagues, I am delighted you are able to join the roundtable discussion and working lunch with Bill Gates on Monday, December 2, from 12:15 AM-1:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with Bill and other staff from the Global Health Program at the BMGF. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than a series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to discuss the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD); Trevor Mundel, President of the Global Health Program at the BMGF; Boris Nikolic, Scientific Advisor; and Kathy Young, Senior Project Manager for Strategic Planning and Engagement. Their bios are attached. Please feel free to contact Rob Eiss at FIC with any questions you or your staff may have surrounding the visit. I'm delighted that Bill was able to reschedule so soon after the shutdown, and will remain on campus a good portion of the day to visit labs and hold discussions with senior leadership, in addition to the presenting the annual David Barmes Global Health lecture. Best regards, Francis In that you comment 1) the state of 2d discussion. id Engagement in ea attached. I am asking Details on the lunch are forthcoming.
-
Dear Colleagues, I am delighted you are able to join the roundtable discussion and working lunch with Bill Gates on Monday, December 2, from 12:15 AM-1:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with Bill and other staff from the Global Health Program at the BMGF. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than a series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to discuss the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD); Trevor Mundel, President of the Global Health Program at the BMGF; Boris Nikolic, Scientific Advisor; and Kathy Young, Senior Project Manager for Strategic Planning and Engagement. Their bios are attached. Please feel free to contact Rob Eiss at FIC with any questions you or your staff may have surrounding the visit. I'm delighted that Bill was able to reschedule so soon after the shutdown, and will remain on campus a good portion of the day to visit labs and hold discussions with senior leadership, in addition to the presenting the annual David Barmes Global Health lecture. Best regards, Francis Dr. Trevor Mundel BIO Dr. Trevor Mundel, president of the Global Health Program, leads the foundation's efforts in research and development of health solutions including vaccines, drugs, and diagnostics, focusing on health problems that have a major impact in developing countries but get too little attention and funding. He oversees the Global Health Program's work which harnesses innovations in science and technology, to fight diseases such as HIV/AIDS, tuberculosis, and malaria. Mundel joined the foundation in 2011. Prior to joining the Gates Foundation, Dr. Mundel served as Head of Global Development Functions for Novartis Pharmaceuticals, where he was is responsible for the development of drug candidates provided by the Novartis Institutes for Biomedical Research (NIBR) or licensing partners. Prior to joining Novartis, Dr. Mundel worked for Warner Lambert and Pfizer in senior clinical development roles including Director in Central Nervous System Clinical Development and Head of Experimental Medicine, respectively. In both instances, Dr. Mundel was recruited to restructure their research and development programs and streamline the process of translating basic research into new drugs. Dr. Mundel is a proponent of modeling and simulation, using mathematical models to optimize and expedite everything from biochemical drug mechanisms to decision-making and profits. Dr. Mundel's appointment may reflect the Gates Foundation's desire to apply that approach to their health and drug development projects. Dr. Mundel holds an M.D. from the University of the Witwatersrand, Johannesburg, South Africa. He also studied Mathematics, Logic and Philosophy at Balliol College of the University Oxford as a Rhodes Scholar and then completed graduate studies in Mathematics at the University of Chicago, where he focused on Dynamical Systems and Neural Networks. Dr. Mundel completed training in Neurology at the University of Chicago Hospitals. Dr. Boris Nikolic BIO Dr. Boris Nikolic is a Scientific Advisor to Bill Gates at Bill Gates Catalyst 3 (bgC3) and at the Bill and Melinda Gates Foundation (BMGF). He received his MD from Zagreb Medical School and his clinical training from the University's Medical Center, University of Zagreb, Croatia. In 1994, Dr. Nikolic joined the Harvard Graduate Program in Immunology (postdoctoral fellowship in transplantation immunology). Subsequently, Dr. Nikolic continued to serve in roles of increasing authority including postdoctoral fellowship, Instructor in Surgery and Medicine to Assistant Professor in Medicine at Harvard Medical School. Between 2002 and 2007, Founder and Director, Advanced Immunology Laboratory for Tolerance Induction Stem Cell Transplantation, Renal Unit, Massachusetts General Hospital-Harvard Medical School. In 2007, Dr. Nikolic joined the BMGF and in 2010 he joined bgC3. Dr. Nikolic is the author of over 70 articles and patent applications and co-founder of three biotechnology companies. Research interests: immunogenetics, immunological tolerance induction for transplant, auto immunity and stem cell research. Ilins and Mr. Bill Gates ! Infectious PROGRAM OF ACTIVITY NIH VISIT OF BILL GATES DECEMBER 2, 2013 9:00 AM Arrival and Greetings (The Dale and Betty Bumpers Vaccine Research Center (VRC) 9:05 AM - 9:45 AM Scientific Tour of the VRC Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases Dr. John Mascola, Director, VRC 10:00 AM - 10:45 AM Media Roundtable (Library Conference Room, Clinical Center) • Associated Press • New York Times • Wall Street Journal • Washington Post 11:00 AM - 12:00 PM David E. Barmes Global Health Lecture (Masur Auditorium, Clinical Center) • 11:00 AM - 11:05 AM Introduction by Dr. Francis Collins • 11:05 AM - 11:40 AM "Why the Future Needs Biomedical Innovation" • 11:40 AM - 12:00 PM Q's and A's 12:15 PM - 1:30 PM Roundtable Discussion with NIH Senior Leadership and Working Lunch Select priorities in global health: state of the science, questions to resolve (Medical Board Room, Clinical Center) • Opening remarks: Dr. Francis Collins and Mr. Bill Gates • HIV, malaria, TB and other infectious disease priorities Lead discussant: Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases Dr. Roger Glass, Director, Fogarty International Center • Understanding the molecular basis of growth and nutrition Lead discussant: Dr. Alan Guttmacher, Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development Dr. Gregory Germino, Deputy Director, National Institute of Diabetes and Digestive and Kidney Diseases ing itute ch Institute . "Bill" Young Center)
-
or In that you comment 1) the state of ad discussion. 2eping flexible ' this format Dear Colleagues, I am delighted you are able to join the roundtable discussion and working lunch with Bill Gates on Monday, December 2, from 12:15 AM-1:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with Bill and other staff from the Global Health Program at the BMGF. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than a series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to discuss the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD); Trevor Mundel, President of the Global Health Program at the BMGF; Boris Nikolic, Scientific Advisor; and Kathy Young, Senior Project Manager for Strategic Planning and Engagement. Their bios are attached. Please feel free to contact Rob Eiss at FIC with any questions you or your staff may have surrounding the visit. I'm delighted that Bill was able to reschedule so soon after the shutdown, and will remain on campus a good portion of the day to visit labs and hold discussions with senior leadership, in addition to the presenting the annual David Barmes Global Health lecture. Best regards, Francis NIAID - BILL & MELINDA GATES FOUNDATION PARTNERSHIPS GLOBAL HEALTH HIGHLIGHTS OF CURRENT ACTIVITIES • Tuberculosis o The TB Biomarker Development Consortium is a collaboration between the NIAID AIDS Clinical Trials Group (ACTG), CDC TB Trials Consortium (CDC/TBTC) and the Global Alliance for Tuberculosis Drug Development (GATB) to facilitate the discovery and qualification of biomarkers for TB treatment outcome using a common sample collection and processing protocol to biobank biologic samples linked to clinical and microbiological data from TB patients during treatment and follow-up. As of mid-2013, biological samples have been collected from 1/3 of the 1000 targeted TB treated patients. Biosamples are anticipated to be available to qualified researchers by 2014/2015. o ACTG is collaborating with the GATB to conduct three clinical studies: ▪ A5306: a Phase I study to evaluate the safety and pharmacokinetic interaction of PA824, an investigational Nitroimidazole for the treatment of tuberculosis, together with efavirenz, ritonavir-boosted lopinavir, or rifampin. This study is closed to follow up. ▪ A5304/REMox: a randomized placebo-controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol, isoniazid, rifampicin and pyrazinamide) followed by four months isoniazid and rifampicin. This study is closed to follow up. ▪ A5289: a randomized controlled Phase II study in intensive phase treatment of drugsensitive TB in HIV infected and uninfected individuals with pulmonary TB. This study is in development. o DMID is collaborating with GATB to conduct a phase 1 study to assess the effects ofsupratherapeutic doses of clofazimine on the QTc interval in healthy subjects. DMID has also collaborated with GATB to conduct a phase 1 study to assess the effects of PA-824 and PA-824 plus moxifloxacin on QTc interval in healthy subjects and to conduct a phase 1 study to assess the interaction of rifabutin or rifampin and bedaquiline in healthy subjects o NIAID is involved in the Critical Paths to TB Drug Regimens (CPTR) initiative (http://cptrinitiative.org/), which is funded by the BMGF. This partnership brings together the world's leading pharmaceutical and other drug developers, global regulatory agencies, and civil society organizations to support advances in regulatory science, the development of infrastructure, and other progress needed to facilitate the development and availability of new TB drug treatments. NIAID staff serve as co-chairs on CPTR working groups to assure coordination with NIAID activities and are represented on the CPTR Advisory Panel (Dr. Fauci or delegate). o The Regional Prospective Observational Research for Tuberculosis (RePORT) project,established under the Indo-U.S. Vaccine Action Program (VAP) Initiative on Tuberculosis Research,was awarded in 2013. The aim of this initiative involving joint teams of Indian and U.S. scientists is to build and enhance biomedical and clinical research capacity in India by establishing long-term longitudinal cohorts of TB patients and their contacts (or other high TB risk patients) for studies using state-of-the art research tools. RePORT is funded jointly by the Government of India's (GOI) Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), the Bill and Melinda Gates Foundation (BMGF), and CRDF Global [utilizing funds provided NIAID and NIH's Office of AIDS Research (OAR)]. After peer review by a panel of TB and HIV experts from the United Statesand India, five teams out of 22 applications were selected for funding. These are: (1) National Institute of Research in Tuberculosis / B.J. Medical College - Johns Hopkins University; (2) Jawaharlal Institute of Postgraduate Medical Education and Research - Boston University / Boston Medical Center; (3) Prof. M. Viswanathan Diabetes Research Centre - University of Massachusetts Medical School; (4) Christian Medical College - University of Washington; and (5) LEPRA - Blue Peter Public Health & Research Centre - CPIDC, Biomedical Research, The University of Texas Health Center Health Science Center at Tyler. In addition, the BMGF has recently awarded funds to CRDF Global to facilitate support for the RePORT India sites that plan to follow house-hold contacts of incidence TB cases, so that the number and quality of specimens collected are adequate to address critical biomarker questions of importance to the TB field, particularly in India. o Through the NIH-funded Clinical Diagnostics Research Consortium, NIAID is collaborating with the Foundation for Innovative New Diagnostics (FIND) to evaluate early stage TB diagnostics in TB endemic countries. Recent studies include the evaluation of the Inverness Urine LAM assay in HIV-positive subjects, evaluation of the TREK MYCOTB MIC plate for susceptibility testing of Mycobacterium tuberculosis and the identification of serological markers for pediatric TB. o DMID staff serve as technical advisors on GATB and AERAS technical working groups to assure NIAID resources are optimally leveraged and coordinated for product development in TB. o NIAID has conducted several workshops in collaboration with AERAS to discuss contemporary issues in TB vaccine discovery and development. o NIAID staff serve as reviewers for applications in response to BMGF Initiatives to assure
-
Dear Colleagues, I am delighted you are able to join the roundtable discussion and working lunch with Bill Gates on Monday, December 2, from 12:15 AM-1:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with Bill and other staff from the Global Health Program at the BMGF. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than a series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to discuss the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD); Trevor Mundel, President of the Global Health Program at the BMGF; Boris Nikolic, strategic Planning and Engagement. Their bios are Scientific Advisor; and Kathy Young, Senior Project Manager for Strategic Planning and Engagement. Their bios are attached. Please feel free to contact Rob Eiss at FIC with any questions you or your staff may have surrounding the visit. I'm delighted that Bill was able to reschedule so soon after the shutdown, and will remain on campus a good portion of the day to visit labs and hold discussions with senior leadership, in addition to the presenting the annual David Barmes Global Health lecture. Best regards, Francis From: HR ensf.gov" HE a nsf.gov> To: bgc3.com" )bgc3.com>, Hila cene.com" Hil@cene.com>, Mniaid.nih.gov" niaid.nih.gov> Subject: Request for Letter of Support for Leroy Hood for the 2013 National Medal of Science Date: Fri, 27 Jan 2012 19:03:12 -0500 Importance: Normal Dear Sir/Madam, Alan Aderem has nominated Leroy Hood for the 2013 National Medal of Science. As part of the nomination process, you have been listed as one of several references for Leroy Hood. Your reference supporting the nomination of Leroy Hood must be submitted by 11:59 PM Eastern Time on March 31, 2012 through FastLane at the following Web site: https://www fastlane.nsf.gov/honawards/. If you are a new user to the Honorary Awards FastLane System, you will have to create a User Name and password before logging in. Thank you. (This is an automatically generated e-mail.) This e-mail was sent from an address that cannot accept incoming e-mail therefore please DO NOT REPLY TO THIS MESSAGE. dential and may contain sensitive information. It acipient. If you have received this e-mail in error other storage devices. The National Institute of for any statements made that are the sender's representatives.